natgillin/translations-raw huggingface dataset:
Based on the data provided, it is considered that the comparability of Syner-Kinase and urokinase products used in the literature studies cited in the submission has been sufficiently demonstrated. 
Na podlagi zagotovljenih podatkov se šteje, da je primerljivost zdravila Syner-Kinase in zdravil, ki vsebujejo urokinazo, iz študij literature, navedene v predložitvi, zadostno dokazana.
The CHMP also requested the MAH/applicant to provide further information to support the viral and prion clearance capacity of the process and justify the adequacy of the procedures to support the suitability of viral and prion removal, including transmissible spongiform encephalopathies (TSE) infectivity reduction. 
Odbor CHMP je tudi zahteval, naj imetnik dovoljenja za promet z zdravilom/predlagatelj zagotovi dodatne informacije, ki dokazujejo sposobnost odstranjevanja virusov in prionov v okviru postopka in ustreznost postopkov za dokazovanje primernosti odstranjevanja virusov in prionov, vključno z zmanjšanjem infektivnosti transmisivnih spongiformnih encefalopatij (TSE).
As part of this procedure, the CHMP requested the applicant to justify that the available data on SynerKinase, including its comparison to the urokinase products mentioned in the literature, are adequate to support its positive benefit/risk balance in the proposed indications. 
V okviru tega postopka je odbor CHMP zahteval, naj predlagatelj dokaže, da so razpoložljivi podatki o zdravilu Syner-Kinase, vključno z njegovo primerjavo z zdravili, ki vsebujejo urokinazo, iz literature, primerni za potrditev njegovega pozitivnega razmerja med tveganji in koristmi pri predlaganih indikacijah.
Finally, the CHMP requested the MAH/applicant to provide further information to demonstrate that the manufacturing steps for semi-purified urokinase have been satisfactorily validated, and also that the control strategy for column lifetime during the manufacture of the active pharmaceutical ingredient is suitable. 
Na koncu je odbor CHMP zahteval, naj imetnik dovoljenja za promet z zdravilom/predlagatelj zagotovi dodatne informacije, ki dokazujejo, da so bili proizvodni koraki za polprečiščeno urokinazo zadovoljivo potrjeni, in tudi, da je strategija nadzora za življenjsko dobo stolpcev med proizvodnjo aktivne farmacevtske učinkovine ustrezna.
The MAH/applicant has provided further comparative studies between Syner-Kinase active ingredient (API) and the API's in the urokinase products used in the literature studies cited in the submission, as well as data demonstrating the consistency of the product overtime despite the changes made to the product during its lifecycle. 
Imetnik dovoljenja za promet/predlagatelj je zagotovil dodatne študije o primerjavi med aktivno učinkovino zdravila Syner-Kinase (API) in aktivnimi učinkovinami v zdravilih, ki vsebujejo urokinazo, iz študij literature, navedene v predložitvi, pa tudi podatke, ki dokazujejo konsistentnost zdravila v določenem obdobju, kljub njegovim spremembam med življenjskim ciklom.
Furthermore, confirmation was required that the semi-purified urokinase is manufactured in accordance with GMP. 
Poleg tega se je zahtevala potrditev, da se polprečiščena urokinaza proizvaja v skladu z dobro proizvodno prakso.
The MAH/applicant has provided relevant data to justify the extrapolation of the data available in the literature on the benefit and risks of urokinase in the indications applied for. 
Imetnik dovoljenja za promet z zdravilom/predlagatelj je zagotovil ustrezne podatke, ki upravičujejo ekstrapolacijo podatkov, ki so na voljo v literaturi o koristih in tveganjih urokinaze pri indikacijah, za katere je bila vložena vloga.
The referral procedure started on 7 November 2012. 
Napotitveni postopek se je začel 7. novembra 2012.
Written explanations were provided by the marketing authorisation holders on 17 June 2013, 10 January 2014 and 12 March 2014. 
Imetniki dovoljenja za promet z zdravilom so pisna pojasnila predložili 17. junija 2013, 10. januarja 2014 in 12. marca 2014.
The Committee adopted a positive opinion by majority on 9 April 2014. 
Zato je 9. aprila 2014 z večino glasov sprejel pozitivno mnenje.
The Committee appointed M. Holzhauser-Alberti as rapporteur and C. Muñoz Madero as co-rapporteur. 
Odbor je imenoval Michaela Holzhauser-Albertija za poročevalca in Cristino Muñoz Madero za soporočevalko.
The final opinion was converted into a Decision by the European Commission on 1 September 2014. 
Končno mnenje je bilo 1. septembra 2014 spremenjeno v sklep Evropske komisije.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the amended summary of product characteristics, labelling and package leaflet in Annex III. 
Seznam zadevnih imen zdravil je naveden v Prilogi I. Znanstveni zaključki so navedeni v Prilogi II, skupaj s spremenjenim povzetkom glavnih značilnosti zdravila, označevanjem in navodilom za uporabo v Prilogi III.
Due to divergent national decisions taken by Member States with respect to target species, indications, posology and withdrawal periods concerning the authorisations of Baytril 2.5% injectable, Baytril 5% injectable and Baytril 10% injectable and their associated names, on 26 October 2012 France referred the issue to the CVMP under Article 34(1) of Directive 2001/82/EC, in order to resolve the divergence in the product information of nationally authorised products across the European Union. 
Zaradi različnih odločitev, ki so jih države članice na nacionalni ravni sprejele glede ciljnih živalskih vrst, indikacij, odmerjanja in karence v zvezi z dovoljenji za promet z zdravilom Baytril 2,5 % raztopina za injiciranje, Baytril 5 % raztopina za injiciranje in Baytril 10 % raztopina za injiciranje in povezana imena, je Francija 26. oktobra 2012 zadevo napotila na odbor CVMP v skladu s členom 34(1) Direktive 2001/82/ES, da bi ta odpravil razlike med informacijami o zdravilu za nacionalno odobrena zdravila po vsej Evropski uniji.
Baytril 2.5% injectable, Baytril 5% injectable and Baytril 10% injectable and their associated names are solutions for injection containing enrofloxacin at 25 mg/ml, 50 mg/ml and 100 mg/ml respectively. 
Zdravila Baytril 2,5 % raztopina za injiciranje, Baytril 5 % raztopina za injiciranje ter Baytril 10 % raztopina za injiciranje in povezana imena so raztopine za injiciranje, ki vsebujejo 25 mg/ml, 50 mg/ml oziroma 100 mg/ml enrofloksacina.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom injiciranje in Baytril 10 % raztopina za injiciranje in povezana imena ostaja pozitivno, če se upoštevajo spremembe v informacijah o zdravilu.
Opinion following an Article 341 referral for Baytril 2.5% injectable, Baytril 5% injectable and Baytril 10% injectable and their associated names 
Mnenje v zvezi z napotitvijo v skladu s členom 340F za zdravila Baytril 2,5 % raztopina za injiciranje, Baytril 5 % raztopina za injiciranje ter Baytril 10 % raztopina za injiciranje in povezana imena
Based on the evaluation of the currently available data, the CVMP considered that the benefit-risk profile of Baytril 2.5% injectable, Baytril 5% injectable and Baytril 10% injectable and their associated names remains positive, subject to amendments in the product information. 
Na podlagi ovrednotenja trenutno razpoložljivih podatkov je odbor CVMP menil, da razmerje med koristmi in tveganji za zdravila Baytril 2,5 % raztopina za injiciranje, Baytril 5 % raztopina za
28 months. 
28 mesecev
After taking one of them, wait at least 2 to 3 hours before taking the other. 
Po zaužitju enega od teh zdravil počakajte vsaj 2 do 3 ure, preden vzamete drugo.
Date of first authorisation: 18/02/2011 Date of latest renewal: 19/11/2015 
Datum prve odobritve: 18/02/2011 Datum zadnjega podaljšanja: 19/11/2015
The INR values increased on average by 13% [CI90 6-19%]. 
Vrednosti INR so se povečale povprečno za 13 % [IZ90 6-19 %].
The results are given in Table 2. 
Rezultati so podani v preglednici 2.
It is estimated that 80-90% of the dose is excreted in faeces, although this has not been confirmed in man. 
Ocenjeno je, da se 80-90 % odmerka izloči z blatom, čeprav to pri človeku ni potrjeno.
• if you have liver disease; 
• če imate bolezen jeter;
Entacapone can be taken with or without food (see section 5.2). 
Entakapon se lahko jemlje s hrano ali brez nje (glejte poglavje 5.2).
The amount of levodopa available to the brain is increased. 
Poveča se količina levodope, ki je na razpolago možganom.
The major part (95%) of the product excreted in urine is conjugated with glucuronic acid. 
Največji delež (95 %) zdravila, ki se izloči z urinom, je konjugiran z glukuronsko kislino.
Therefore, do not take Entacapone Teva and iron supplements at the same time. 
Zato ne jemljite zdravila Entakapon Teva in dodatkov železa istočasno.
4.5% (0 h 35 min) CI95% 0.93%, 7.97% 
4,5 % (0 h 35 min) IZ95 % 0,93 %, 7,97 %
1 h 20 min CI95% 45 min, 1 h 56 min 
1 h 20 min IZ95 % 45 min, 1 h 56 min
In animal studies entacapone was excreted in milk. 
V študijah na živalih se je entakapon izločal v mleko.
In individual cases, only some of these symptoms and/or findings may be evident. 
Pri posameznih primerih se lahko pokažejo le nekateri od teh simptomov ali laboratorijskih izvidov ali obojega.
Other important side effects which may occur: 
Drugi pomembni neželeni učinki, ki se tudi lahko pojavijo:
Cardiac disorders** 
Srčne bolezni**
• if you are taking certain antidepressants (ask your doctor or pharmacist whether your antidepressive medicine can be taken together with Entacapone Teva); 
• če jemljete določene antidepresive (povprašajte svojega zdravnika ali farmacevta, ali lahko jemljete svoje zdravilo proti depresiji skupaj z zdravilom Entakapon Teva);
A small amount of entacapone, the (E)-isomer, is converted to its (Z)-isomer. 
Majhna količina entakapona, izomera (E), se spremeni v njegovo izomero (Z).
Approximately 92% of the dose is eliminated during ß-phase with a short elimination half-life of 30 minutes. 
Približno 92 % odmerka se odstrani iz telesa v fazi ß s kratkim razpolovnim časom odstranjevanja iz telesa 30 minut.
TEVA Pharmaceutical Works Private Limited Company Pallagi út 13, 4042 Debrecen Hungary 
TEVA Pharmaceutical Works Private Limited Company Pallagi út 13, 4042 Debrecen Madžarska
Management of acute overdose is symptomatic. 
Zdravljenje akutnega prevelikega odmerjanja je simptomatsko.
In the event of prolonged or persistent diarrhoea, the medicinal product should be discontinued and appropriate medical therapy and investigations considered. 
V primeru dolgotrajne ali trdovratne diareje je treba zdravljenje prekiniti in razmisliti o ustreznem zdravljenju in preiskavah.
Entacapone may be used with selegiline (a selective MAO-B inhibitor), but the daily dose of selegiline should not exceed 10 mg. 
Entakapon se sme uporabljati s selegilinom (selektivni zaviralec MAO-B), vendar dnevni odmerek selegilina ne sme preseči 10 mg.
The (E)-isomer accounts for 95% of the AUC of entacapone. 
Izomera (E) predstavlja 95 % AUC entakapona.
• if you are allergic to entacapone or any of the other ingredients of this medicine (listed in section 6); 
• če ste alergični na entakapon ali katero koli sestavino tega zdravila (navedeno v poglavju 6);
Reduction of levodopa dosage decreases the severity and frequency of these reactions. 
Zmanjšanje odmerjanja levodope zmanjša stopnjo izraženosti in pogostost teh učinkov.
Entacapone and iron preparations should be taken at least 2-3 hours apart (see section 4.8). 
Entakapon in pripravke železa je treba jemati s časovnim presledkom vsaj 2-3 ur (glejte poglavje 4.8).
Pharmacokinetic interaction with benserazide has not been studied. 
Farmakokinetičnih interakcij z benserazidom niso proučevali.
Of the metabolites found in urine only about 1% have been formed through oxidation. 
Od presnovkov, ki so v urinu, jih le okrog 1 % nastane z oksidacijo.
The pharmacokinetic properties of entacapone are similar in both young and elderly adults. 
Značilnosti pri bolnikih Farmakokinetične lastnosti entakapona so podobne tako pri mlajših kot pri starejših odraslih osebah.
The total clearance of entacapone is about 800 ml/min. 
Celotni očistek entakapona je okrog 800 ml/min.
Isolated cases of rhabdomyolysis have been reported. 
Poročali so o posameznih primerih rabdomiolize.
COMT inhibition in red blood cells closely follows the plasma concentrations of entacapone, thus clearly indicating the reversible nature of COMT inhibition. 
Inhibicija COMT v rdečih krvničkah je tesno povezana s plazemsko koncentracijo entakapona, kar jasno kaže na reverzibilno naravo inhibicije COMT.
Entacapone binds to human albumin binding site II which also binds several other medicinal products, including diazepam and ibuprofen. 
Entakapon se veže na humanem albuminu na vezavno mesto II, kamor se vežejo tudi številna druga zdravila, vključno z diazepamom in ibuprofenom.
• if you have ever suffered from a rare reaction to antipsychotic medicines called neuroleptic malignant syndrome (NMS). 
• če ste kdaj imeli redko reakcijo na antipsihotična zdravila, ki se imenuje nevroleptični maligni sindrom (NMS).
Entacapone showed little or no inhibition of other types of P450 isoenzymes (CYP1A2, CYP2A6, CYP2D6, CYP2E1, CYP3A and CYP2C19) (see section 
Entakapon je le malo oziroma sploh ni zaviral drugih vrst izoencimov P450 (CYP1A2, CYP2A6, CYP2D6, CYP2E1, CYP3A in CYP2C19) (glejte poglavje
However, in an interaction study with healthy volunteers, entacapone did not change the plasma levels of S-warfarin, while the AUC for R-warfarin increased on average by 18 % [CI90 11-26%]. 
Vendar v študiji medsebojnega delovanja na zdravih prostovoljcih entakapon ni spremenil plazemskih koncentracij S-varfarina, medtem ko se je AUC za R-varfarin povečala povprečno za 18 % [IZ90
The peak concentration (Cmax) in plasma is usually reached about one hour after ingestion of a 200 mg entacapone tablet. 
Največja koncentracija (Cmax) v plazmi se navadno doseže približno eno uro po zaužitju 200 mg tablete entakapona.
Week 8-24 66.8±14.5 
razlika izhodišče teden 8-24 66,8 ± 14,5
The safety and efficacy of Entacapone Teva in children below age 18 have not been established. 
Varnost in učinkovitost zdravila Entakapon Teva pri otrocih starih do 18 let nista bili dokazani.
Clinical interaction studies with diazepam and non-steroidal antiinflammatory medicinal products have not been carried out. 
Klinične študije medsebojnega delovanja z diazepamom in nesteroidnimi protivnetnimi zdravili niso opravljene.
(≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data, since no valid estimate can be derived from clinical trials or epidemiological studies). 
Uporabljen je naslednji dogovor: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000), pogostnost neznana (je ni mogoče oceniti iz razpoložljivih podatkov, ker na podlagi kliničnih preskušanj ali epidemioloških študij ni mogoče ugotoviti zanesljivih ocen pogostnosti).
• if you have ever suffered from a rare muscle disorder called rhabdomyolysis which was not caused by injury. 
• če ste imeli kdaj redko bolezen mišic, ki se imenuje rabdomioliza, in je ni povzročila poškodba.
Do not stop taking Entacapone Teva unless your doctor tells you to. 
Ne prekinite jemanja zdravila Entakapon Teva, razen če vam to naroči vaš zdravnik.
If you experience such effects at the start of treatment with Entacapone Teva you should contact your doctor who may decide to adjust your dosage of levodopa. 
Če pri vas pride od takih učinkov na začetku zdravljenja z zdravilom Entakapon Teva, morate obvestiti zdravnika, ki se bo morda odločil, da vam prilagodi odmerjanje levodope.
The safety of entacapone in infants is unknown. 
Varnost entakapona za dojenčke ni znana.
Entacapone is extensively bound to plasma proteins, mainly to albumin. 
Entakapon se v veliki meri veže na plazemske beljakovine, predvsem na albumine.
EU/1/10/665/001 - 30 tablets EU/1/10/665/002 - 60 tablets EU/1/10/665/003 - 100 tablets EU/1/10/665/004 - 175 tablets 
EU/1/10/665/001 - 30 tablet EU/1/10/665/002 - 60 tablet EU/1/10/665/003 - 100 tablet EU/1/10/665/004 - 175 tablet
This leads to a higher levodopa AUC. 
To povzroči večjo AUC levodope.
• if you have a tumour of the adrenal gland (known as pheochromocytoma; this may increase the risk of severe high blood pressure); 
• če imate tumor nadledvičnice (ti. feokromocitom, ki lahko poveča tveganje za zelo visok krvni tlak);
As there is no experience in pregnant women, entacapone should not be used during pregnancy. 
Ker z zdravljenjem z entakaponom pri nosečnicah ni izkušenj, ga med nosečnostjo ne smete uporabljati.
Entacapone inhibits the COMT enzyme mainly in peripheral tissues. 
Entakapon zavira encim COMT večinoma v perifernih tkivih.
EU/1/10/665/002 - 60 tablets EU/1/10/665/003 - 100 tablets EU/1/10/665/004 - 175 tablets 
EU/1/10/665/002 - 60 tablet EU/1/10/665/003 - 100 tablet EU/1/10/665/004 - 175 tablet
After absorption from the gastrointestinal tract, entacapone is rapidly distributed to the peripheral tissues with a distribution volume of 20 litres at steady state (Vdss). 
Po absorpciji iz prebavil se entakapon hitro porazdeli v periferna tkiva s porazdelitvenim volumnom 20 litrov v stanju dinamičnega ravnovesja (Vdss).
The post-marketing data include isolated cases of overdose in which the reported highest daily dose of entacapone has been 16,000 mg. 
V postmarketinških podatkih so opisani primeri prevelikega odmerjanja, med katerimi je bil največji opisan dnevni odmerek entakapona 16.000 mg.
Entacapone (n=85) Placebo (n=86) 
placebo (n=86)
Absorption There are large intra- and interindividual variations in the absorption of entacapone. 
Absorpcija V absorpciji entakapona so velike intra- in interindividualne variacije.
It is a reversible, specific, and mainly peripherally acting COMT inhibitor designed for concomitant administration with levodopa preparations. 
Je reverzibilen, specifičen in pretežno na periferiji delujoč zaviralec COMT, namenjen sočasni uporabi s pripravki levodope.
Data from in vitro studies using human liver microsomal preparations indicate that entacapone inhibits cytochrome P450 2C9 (IC50 ~4 μM). 
Podatki iz študij in vitro na preparatih mikrosomov človeških jeter kažejo, da entakapon zavira citokrom P450 2C9 (IC50 ∼4 µM).
** The incidence rates of myocardial infarction and other ischemic heart disease events (0.43% and 1.54%, respectively) are derived from an analysis of 13 double-blind studies involving 2082 patients with end-of-dose motor fluctuations receiving entacapone. 
** Pogostnost miokardnega infarkta (0,43 %) in drugih dogodkov v zvezi z ishemično boleznijo srca (1,54 %) temelji na rezultatih analize podatkov iz 13 dvojno slepih študij, v katere je bilo vključenih 2.082 bolnikov, ki so imeli motorična nihanja ob koncu delovanja odmerka in so prejemali entakapon.
Caution should be exercised when these medicinal products are used concomitantly with entacapone (see also sections 4.3 and 4.4). 
Pri sočasni uporabi teh zdravil z entakaponom je potrebna previdnost (glejte tudi poglavji 4.3 in 4.4).
305, 74770 Opava-Komarov Czech Republic 
305, 74770 Opava-Komarov
Some of the adverse reactions, such as dyskinesia, nausea, and abdominal pain, may be more common with the higher doses (1,400 to 2,000 mg per day) than with the lower doses of entacapone. 
Nekateri neželeni učinki, kot so diskinezija, navzea in bolečine v trebuhu, so pri višjih odmerkih entakapona (1.400 do 2.000 mg dnevno) lahko pogostejši kot pri nižjih odmerkih.
Follow the instructions that your doctor has given you. 
Upoštevajte zdravnikova navodila.
Consequently, adverse dopaminergic reactions may be more frequent when entacapone is added to levodopa/benserazide treatment (see also section 4.8). 
Zato so lahko neželeni dopaminergični učinki pogostejši, kadar je entakapon dodan zdravljenju z levodopo/benserazidom (glejte tudi poglavje 4.8).
if you experience increasing loss of appetite, weakness, exhaustion and weight loss within a relatively short period of time, a general medical evaluation including liver function should be considered. 
• če vedno bolj izgubljate apetit, če pride do oslabelosti, izčrpanosti in izgube telesne mase v razmeroma kratkem obdobju, je treba razmisliti o splošnem zdravniškem pregledu, vključno z oceno jetrne funkcije.
For the characteristics of NMS see Section 4 Possible side effects. 
Za značilnosti NMS glejte poglavje 4 Možni neželeni učinki;
Dyskinesias (27%), nausea (11%), diarrhoea (8%), abdominal pain (7%) and dry mouth (4.2%) were reported significantly more often with entacapone than with placebo in pooled data from clinical studies involving 406 patients taking the medicinal product and 296 patients taking placebo. 
Pri jemanju entakapona so bistveno pogosteje poročali o diskinezijah (27 %), navzei (11 %), driski (8 %), bolečinah v trebuhu (7 %) in suhih ustih (4,2 %) kot pri jemanju placeba po podatkih, združenih iz kliničnih študij s 406 bolniki, ki so jemali zdravilo, in 296 bolniki, ki so jemali placebo.
Very rare: 
zelo redki:
If you forget to take the Entacapone Teva tablet with your levodopa dose, you should continue the treatment by taking the next Entacapone Teva tablet with your next levodopa dose. 
Če pozabite vzeti tableto Entakapon Teva s svojim odmerkom levodope, nadaljujte zdravljenje tako, da vzamete naslednjo tableto Entakapon Teva z naslednjim odmerkom levodope.
The acute symptoms and signs in these cases of overdose included confusion, decreased activity, somnolence, hypotonia, skin discolouration and urticaria. 
Pri teh primerih so akutni simptomi in znaki obsegali zmedenost, zmanjšano aktivnost, zaspanost, hipotonijo, obarvanost kože in urtikarijo.
Week 8-24 10.7±2.2 
razlika izhodišče teden 8-24 10,7 ± 2,2
You may also use other medicines to treat Parkinson's disease at the same time. 
Sočasno lahko jemljete tudi druga zdravila za zdravljenje Parkinsonove bolezni.
What Entacapone Teva is and what it is used for 
Kaj je zdravilo Entakapon Teva in za kaj ga uporabljamo
Because of its mechanism of action, entacapone may interfere with the metabolism of medicinal products containing a catechol group and potentiate their action. 
Zaradi svojega mehanizma delovanja lahko entakapon ovira presnovo zdravil, ki vsebujejo kateholno skupino, in povečuje njihove učinke.
In two phase III double-blind studies in a total of 376 patients with Parkinson's disease and end-ofdose motor fluctuations, entacapone or placebo was given with each levodopa/dopa decarboxylase inhibitor dose. 
V dveh dvojno slepih študijah tretje faze, ki sta zajeli skupno 376 bolnikov s Parkinsonovo boleznijo in motoričnimi fluktuacijami na koncu delovanja odmerka, so bolniki dobivali entakapon ali placebo skupaj z vsakim odmerkom levodope/zaviralca DOPA-dekarboksilaze.
Entacapone is indicated as an adjunct to standard preparations of levodopa/benserazide or levodopa/carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations. 
Entakapon je indiciran kot dodatno zdravilo pri zdravljenju z običajnimi pripravki levodope/benserazida ali levodope/karbidope za uporabo pri odraslih bolnikih s Parkinsonovo boleznijo in motoričnimi nihanji ob koncu delovanja odmerka, ki jih ni mogoče stabilizirati z navedenimi kombinacijami.
If you are receiving dialysis for renal insufficiency, your doctor may tell you to increase the time between doses. 
Če se zaradi insuficience ledvic zdravite z dializo, vam lahko zdravnik naroči, da podaljšate čas med dvema odmerkoma.
What you need to know before you take Entacapone Teva Do NOT take Entacapone Teva 
Kaj morate vedeti, preden boste vzeli zdravilo Entakapon Teva NE jemljite zdravila Entakapon Teva